BeiGene In Deal-Making Mood Following US IPO
This article was originally published in PharmAsia News
Executive Summary
Chinese venture BeiGene is aiming to transform itself in the wake of a US IPO, hoping to attract more partnering deals as it focuses on progressing its pipeline and fast-tracking its anticancer assets, amid an improving Chinese environment for new drug development.